Crestor May Be Safer Than Other Statins, FDA Tells Public CitizenLee Kalowski
HDL-C increases by dose in patients with hyperlipidemia or mixed dyslipidemia treated with CRESTOR vs other statins[3a], [4a]. Adapted from the STELLAR Trial. At 6 weeks in the STELLAR Trial: Patients who were on a 10 mg dose of CRESTOR achieved a mean 7.7%[*] change from baseline HDL...
The risk of myopathy during treatment with CRESTOR may be increased in Asian patients and with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), cyclosporine, teriflunomide, enasidenib, capmatinib, fostamatinib, febuxostat, gemfibrozil, tafamidis, darolutamide, ...
996 controls did not find a significantteratogeniceffect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders – includingmaternal age,diabetesmellitus,hypertension,obesity, and alcohol and tobacco use – using propensity score-based method...